Arthur M. Cohen & Associates’s Gilead Sciences GILD Stock Holding History

Arthur M. Cohen & Associates’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$410K	Sell	2,920 -110	-4%	-$15.4K	0.07%	91
2025 Q4	$372K	Buy	3,030 +520	+21%	+$63.2K	0.06%	97
2025 Q3	$279K	Sell	2,510 -1,010	-29%	-$115K	0.05%	112
2025 Q2	$390K	Buy	3,520 +1,000	+40%	+$106K	0.07%	96
2025 Q1	$282K	Buy	2,520 +10	+0.4%	+$1.03K	0.05%	108
2024 Q4	$232K	Hold	2,510	–	–	0.04%	127
2024 Q3	$211K	Sell	2,510 -1,150	-31%	-$87.8K	0.04%	136
2024 Q2	$251K	Buy	3,660 +925	+34%	+$61.7K	0.05%	125
2024 Q1	$200K	Buy	2,735 +110	+4%	+$8.46K	0.04%	134
2023 Q4	$213K	Buy	+2,625	New	+$204K	0.05%	129

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Arthur M. Cohen & Associates's GILD Position: Q1 2026 in Review

Arthur M. Cohen & Associates reduced its Gilead Sciences (GILD) stake by 3.6% in Q1 2026, selling an estimated $15.4K and leaving 2,920 shares worth $410K. The position accounts for 0.07% of the portfolio, ranked #91.

Arthur M. Cohen & Associates first reported a position in GILD in Q4 2023 and has held it in 10 quarters since. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

Arthur M. Cohen & Associates held 2,920 shares of Gilead Sciences worth $410K as of Q1 2026.
Arthur M. Cohen & Associates sold 110 Gilead Sciences shares in Q1 2026, an estimated $15.4K.
Gilead Sciences made up 0.07% of Arthur M. Cohen & Associates's portfolio in Q1 2026, its #91 holding.
Arthur M. Cohen & Associates first reported a position in Gilead Sciences in Q4 2023 and has held it in 10 quarters since.
2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on Arthur M. Cohen & Associates's 13F filing for Q1 2026, filed 8 May 2026.